Overview

A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma

Status:
Completed

Trial end date:
2021-01-27

Target enrollment:

Participant gender:

Summary

A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial Cancer, Epithelial Ovarian Cancer, or Carcinosarcoma

Phase:

Phase 2

Details

Lead Sponsor:

Leap Therapeutics, Inc.

Treatments:

Paclitaxel